Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
The last earnings update was 48 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Corvus Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Corvus Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Corvus Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Corvus Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Corvus Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Corvus Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Corvus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Corvus Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Corvus Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Corvus Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Richard A. Miller, also known as Rick, M.D., is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Officer, President and Chairman since February 2014 and January 2014 respectively. Dr. Miller has been Chief Commercialization Officer and Research Professor at The University of Texas at Austin since September 2010. Dr. Miller founded Principia Biopharma Inc. in 2008 and served as its President and Chief Executive Officer. He also serves as an Advisor at VantagePoint Capital Partners. In 1992, Dr. Miller founded Pharmacyclics Inc. and was its Chief Executive Officer. Dr. Miller co-founded IDEC Pharmaceuticals Corporation in 1985 and from 1984 to February 1992 served as its Vice President of Research and Clinical. He served as a Director of Principia Biopharma Inc. He has been a Director at Pharmacyclics Inc., since April 1991. He serves as an Executive Director at Corvus Pharmaceuticals, Inc. Dr. Miller served as a Director at Galileo Pharmaceuticals, Inc. and IDEC Pharmaceuticals Corporation. He has been Adjunct Clinical Professor at Medicine in Oncology at Stanford University Medical Center since 1991, where Dr. Miller has ongoing teaching and patient care responsibilities. After receiving an M.D. degree, he continued his career at Stanford as a Research Scientist in Cancer Biology and Immunology where Dr. Miller pioneered the use of monoclonal antibodies for the treatment of lymphomas. He is the author of over 100 scientific publications and numerous issued patents and is a frequently invited speaker at various scientific and business conferences. Dr. Miller received an M.D. degree, summa cum laude, from the State University of New York in 1975 and was trained in Internal Medicine and Medical Oncology at Stanford University Medical Center and is Board Certified in both specialties. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College.
Rick's compensation has been consistent with company performance over the past year.
Rick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Corvus Pharmaceuticals management team is about average.
Chief Financial Officer
Senior VP & Chief Business Officer
Co-Founder & Executive VP of Discovery Research
Senior Vice President of Pharmaceutical Development
VP & Chief Medical Officer
Vice President of Chemistry Research
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Corvus Pharmaceuticals board of directors is about average.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.